Helena Florindo

Drug Delivery & Immunoengineering

Our research is focused on the characterization of the mechanisms of cellular dynamics, cross-talk and networks, to identify new targets that will guide the engineering of translational nanotechnology-based systems for drug delivery, imaging and immunotherapy in specific clinically relevant situations (cancer, inflammation, infectious and genetic diseases).

Translational drug delivery systems (Emerging technologies)

Development of scalable formulation procedures for the delivery of small molecules, oligonucleotides (e.g., mRNA, siRNA, miRNA), proteins, peptides via several administration routes (e.g.  parenteral, pulmonary, transdermal, ocular, nasal and oral) for the treatment and diagnosis of cancer, inflammatory and infectious diseases.

Multifunctional delivery systems for immunomodulation (Oncology)

Development of multivalent systems to modulate the recognition, capture, processing and presentation of antigens by dendritic cells, against cancer. It includes the association of nanovaccines with chemo-immunotherapeutic agents designed to modulate the function and activation of immune and stromal cells within tumor site.

Bridging biophysics and cell biology to improve therapeutics’ efficacy and safety (Emerging Technologies)

We apply advanced fluorescence microscopy methodologies to characterize the interaction of therapeutics with cell membranes, and subsequent impact on cell function and pathology. We apply this knowledge in the development of safe and efficacious therapies addressing unmet medical needs.

Advanced vaccine drug delivery formulations (Infectious diseases)

Development of multivalent systems suitable for the delivery of combinations of antigens (mRNA, proteins, peptides) and adjuvants (e.g. lipids, oligonucleotides) to modulate the recognition, capture, processing and presentation of antigens by dendritic cells. We modulate the physicochemical properties of our disruptive platforms accordingly to the desired administration route, and thereby to the site of action.

Carreira AC, Pokorna S, Ventura AE, Walker MW, Futerman, AH, Lloyd-Evans E, de Almeida RFM, Silva LC. Biophysical impact of sphingosine and other abnormal lipid accumulation in Niemann-Pick disease type C cell models. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866: 158944. DOI: 10.1016/j.bbalip.2021.158944.
Costa C, Liu A, Simoes SI, Correia A, Rahikkala A, Seitsonen J, Ruokolainen J, Aguiar-Ricardo A, Santos HA, Corvo ML. One-step microfluidics production of enzyme-loaded liposomes for the treatment of inflammatory diseases. Colloids Surf B Biointerfaces 199 (2021) 111556. DOI: 10.1016/j.colsurfb.2020.111556.
Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro R. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020; 15 :630-645. DOI: 10.1038/s41565-020-0732-3.
Conceição J, Farto-Vaamonde X, Goyanes A, Adeoye O, Concheiro A, Cabral-Marques H, Sousa Lobo JM, Alvarez-Lorenzo C. Hydroxypropyl-β-cyclodextrin-based fast dissolving carbamazepine printlets prepared by semisolid extrusion 3D printing. Carbohydr Polym. 2019; 221: 55-62. DOI: 10.1016/j.carbpol.2019.05.084.
Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos AI, Kleiner R, Moura LIF, Zupančič E, Viana AS, Doron H, Gois PMP, Erez N, Jung S, Satchi-Fainaro R, Florindo HF. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019; 14: 891-901. DOI: 10.1038/s41565-019-0512-0.

Helena Florindo

Group Leader

Email: hflorindo@ff.ulisboa.pt

Phone: (+351) 217946400 (Ext.14244)

View Profile
[lab_researchers_otherinfo_shortcode_output]
Back To Top
Come meet us at

Faculdade de Farmácia da Universidade de Lisboa | Av. Professor Gama Pinto
1649-003 Lisboa | Portugal


Phone | +351 217 946 400
Fax | +351 217 946 470
Web | www.imed.ulisboa.pt
Email | imed.ulisboa@ff.ulisboa.pt

Social